Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL10-siRNA
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
CXCL10-siRNA is a small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of the chemokine CXCL10 (IP-10). In epithelial ovarian cancer (EOC), particularly in PD-L1-negative and BRCA2-wild type tumors, CXCL10 is upregulated and plays a critical role in immune evasion by promoting the infiltration and activation of FOXP3+ regulatory T cells (Tregs). Research from Yale University indicates that silencing CXCL10 using siRNA can reduce Treg-mediated immunosuppression, increase IFNγ production, and restore the activity of CD8+ effector and CD4+ helper T cells. This approach is being explored as a novel immunotherapy to overcome resistance and improve outcomes in ovarian cancer patients.
- Other names
- CXCL10 small interfering RNACXCL-10 small interfering RNACXCL 10 small interfering RNA
02
Targets
CXCL10 (C-X-C Motif Chemokine Ligand 10)
Beyond the preview
Go deeper on CXCL10-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL10-siRNA.